CoChat

Acute effect of Ceylon cinnamon extract on postprandial glycemia: alpha-amylase inhibition, starch tolerance test in rats, and randomized crossover clinical trial in healthy volunteers

Open access

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index; 11 of the 34 sources its claims cite were checked for support.

Abstract

BACKGROUND: Postprandial hyperglycemia is a known risk factor for the development of several health disorders including type 2 diabetes, obesity, oxidative stress, and cardiovascular diseases. One encouraging approach for a better control of postprandial glycemia is to reduce carbohydrate digestion. Cinnamon extracts have been known for managing blood glucose. However, their effects on inhibiting digestion of carbohydrate have been poorly analyzed to date. The aim of this study was to investigate the acute effect of a specific Ceylon cinnamon hydro-alcoholic extract (CCE) on carbohydrate digestion and post-meal blood glucose reduction. METHODS: In vitro enzymatic assays and in vivo starch tolerance tests in rats were designed as preclinical assays. Then, a randomized, double-blind, placebo-controlled, cross-over clinical trial was conducted in 18 healthy female and male volunteers. Following the intake of 1 g of CCE, the subjects ate a standardized meal. Blood samples were collected during the 2 hours following the meal to measure glucose and insulin concentrations. Areas under the curves were calculated and statistical differences between the CCE and placebo groups were analyzed using the Mann Whitney-Wilcoxon test. RESULTS: CCE has demonstrated in the in vitro study that it inhibited pancreatic alpha-amylase activity with an IC50 of 25 μg/mL. In the in vivo study, CCE was shown to acutely reduce the glycemic response to starch in a dose-dependent manner in rats. This effect was significant from the dose of 12.5 mg/kg of body weight. In both, the in vitro and in vivo studies, the hydro-alcoholic extract has shown to be more efficacious than the aqueous extract. In the human clinical trial, 1 g of CCE lowered the area under the curve of glycemia between 0 and 120 min by 14.8% (P = 0.15) and between 0 and 60 min by 21.2% (P < 0.05) compared to the placebo. This effect occurred without stimulating insulin secretion. No adverse effects were reported. CONCLUSION: These results suggest that Ceylon cinnamon hydro-alcoholic extract (CCE) may provide a natural and safe solution for the reduction of postprandial hyperglycemia and therefore help to reduce the risks of developing metabolic disorders. TRIAL REGISTRATION: ClinicalTrials.gov NCT02074423 (26/02/2014).

Overview

CoChat Summary

TL;DR

This study tested a hydro-alcoholic Ceylon cinnamon extract (CCE) for acute postprandial glycemia using α-amylase inhibition, rat starch tolerance tests, and a randomized crossover trial in healthy volunteers. CCE inhibited pancreatic α-amylase and reduced starch glycemic responses in rats and humans, with a 21.2% reduction in 0–60 min glucose AUC in humans without stimulating insulin.

Key findings

  • In vitro, CCE inhibited porcine pancreatic α-amylase with an IC50 of 25 μg/mL; acarbose had an IC50 of 18 μg/mL. The hydro-alcoholic extract was stronger than an aqueous extract (IC50 30 vs 40 μg/mL).
  • In rats, CCE reduced the glycemic response to starch dose-dependently: AUC 0–120 min reductions were 3.2%, 10.1%, 14.5%, 22.5%, and 30.7% at 6.25, 12.5, 25, 50, and 100 mg/kg, respectively, significant from 12.5 mg/kg. At 50 mg/kg, CCE reduced the glycemic response by 20.4% (P < 0.05) and blunted the insulin peak by 40.6% (AUC 0–60 min P < 0.05; AUC 0–120 min P = 0.13).
  • In the human trial, 1 g CCE before a standard meal reduced glycemia AUC 0–120 min by 14.8% (P = 0.15) and AUC 0–60 min by 21.2% (P < 0.05) versus placebo. No significant difference in insulin response was observed, and no adverse effects were reported.

Methods

  • Preclinical assays included an in vitro pancreatic α-amylase inhibition assay using porcine pancreatic α-amylase and gelatinized potato starch, with acarbose as positive control, and acute starch tolerance tests in overnight-fasted male Wistar Han IGS rats given oral gavage of 1.5 g/kg wheat starch, with blood glucose and insulin measured over 120 min.
  • The clinical study was a monocentric, randomized, double-blind, placebo-controlled crossover trial in 18 healthy volunteers (11 male/7 female; age 29.9 ± 1.8 years; BMI 21.4 ± 0.4 kg/m²). Participants received 1 g CCE (two 500 mg capsules) or placebo 30 min before a standardized white bread meal; capillary glucose and venous insulin were measured over 120 min.
  • The primary endpoint was glycemia AUC 0–120 min. Analyses used ITT and per-protocol populations, ANOVA, paired Student’s t-test or Koch method, and Mann Whitney-Wilcoxon test, with significance at P < 0.05.

Limitations

  • The paper states that the 0–120 min human glycemic reduction was not statistically significant (P = 0.15), and suggests that increasing subject numbers might have made it significant or that selecting subjects with impaired glucose tolerance could be an alternative. It also states that other human clinical trials are required to confirm results and assess other health benefits.
  • The trial enrolled healthy volunteers with normal glucose tolerance and excluded IGT subjects, so findings may not generalize to impaired glucose tolerance or diabetic populations; this is evident from the inclusion/exclusion criteria and discussion.
  • The study was acute and single-dose, with a small sample (18 randomized; 16 per-protocol for some analyses), and no long-term outcomes were assessed; these limitations are evident from the design and reported sample size.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/1472-6882-14-351

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Alpha-amylase inhibitory effect of CCE. Values represent mean of triplicate measures.
Figure 1 Alpha-amylase inhibitory effect of CCE. Values represent mean of triplicate measures.CC BY · PubMed Central
Figure 2 Effect of CCE on blood glucose and insulin response during a STT in rats. Acute effect of CCE at the dose of 50 mg/kg of body weight on blood glucose response (A) and on insulin response (B) during STT in normal rats. Values represent mean ± SEM, n = 8. Time points different from control, Student’s t-test *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 2 Effect of CCE on blood glucose and insulin response during a STT in rats. Acute effect of CCE at the dose of 50 mg/kg of body weight on blood glucose response (A) and on insulin response (B) during STT in normal rats. Values represent mean ± SEM, n = 8. Time points different from control, Student’s t-test *P < 0.05; **P < 0.01; ***P < 0.001.CC BY · PubMed Central
Figure 3 Dose-effect of CCE on blood glucose during a STT in rat. Acute dose-effect of CCE on blood glucose response during STT in normal rats, (A) AUC 0–120 min, (B) Logarithmic regression of CCE dose-effect. Values represent mean ± SEM, n = 8. AUC different from control, Student’s t-test *P < 0.05; ***P < 0.001.
Figure 3 Dose-effect of CCE on blood glucose during a STT in rat. Acute dose-effect of CCE on blood glucose response during STT in normal rats, (A) AUC 0–120 min, (B) Logarithmic regression of CCE dose-effect. Values represent mean ± SEM, n = 8. AUC different from control, Student’s t-test *P < 0.05; ***P < 0.001.CC BY · PubMed Central
Figure 4 Comparison of the effects of hydro-alcoholic and aqueous cinnamon extracts. (A) Blood glucose response during STT in normal rats. Values represent mean ± SEM, n = 20. Student’s t-test: *P < 0.05; **P < 0.01; ***P < 0.001 different from control; #P < 0.05; ##P < 0.01 different from aqueous cinnamon extract. (B) In vitro α-amylase inhibition. Values represent mean of triplicate measures.
Figure 4 Comparison of the effects of hydro-alcoholic and aqueous cinnamon extracts. (A) Blood glucose response during STT in normal rats. Values represent mean ± SEM, n = 20. Student’s t-test: *P < 0.05; **P < 0.01; ***P < 0.001 different from control; #P < 0.05; ##P < 0.01 different from aqueous cinnamon extract. (B) In vitro α-amylase inhibition. Values represent mean of triplicate measures.CC BY · PubMed Central
Figure 5 Flow diagram of clinical study participants.
Figure 5 Flow diagram of clinical study participants.CC BY · PubMed Central
Figure 6 Effect of 1 g CCE on blood glucose and insulin response after a standard meal in humans. (A) Blood glucose concentration over 120 min, (B) Glycaemia AUC 0–120 min, (C) Glycemia AUC 0–60 min, and (D) Insulin concentrations over 120 min. Values represent mean ± SEM, n = 16.% of inhibition of test meal glycemic response is indicated. CCE different from placebo, *P < 0.05.
Figure 6 Effect of 1 g CCE on blood glucose and insulin response after a standard meal in humans. (A) Blood glucose concentration over 120 min, (B) Glycaemia AUC 0–120 min, (C) Glycemia AUC 0–60 min, and (D) Insulin concentrations over 120 min. Values represent mean ± SEM, n = 16.% of inhibition of test meal glycemic response is indicated. CCE different from placebo, *P < 0.05.CC BY · PubMed Central

Verification

Claims the paper makes

5 Valid · 2 Not valid · 17 Not checked · 67 Own results and interpretations

41 more claims

Create a free account to see all 91 claims and to verify the 23 references still open.

See all claims — free account
  • Probably not a substantial claim. 27
  • It may state two separate claims as one. 20

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Cited by

See all 100

Metadata

Authors
Beejmohun, V., Peytavy-Izard, M., Mignon, C., Muscente-Paque, D., Deplanque, X., Ripoll, C., & Chapal, N.
Affiliations
Eurasanté (FR)
Corresponding author
Chapal, Nicolas
Venue
BMC Complementary and Alternative Medicine
Published
2014-09-23
Volume
14
Issue
1
Pages
351-351
ISSN
1472-6882 (ISSN-L)
OpenAlex
W2172032394
Cited by
97
References
33
Citations by year
2025: 7 · 2024: 15 · 2023: 5 · 2022: 16 · 2021: 7 · 2020: 10 · 2019: 4 · 2018: 8 · 2017: 12 · 2016: 6 · 2015: 6 · 2014: 1
FWCI
6.71
Type
journal article
Language
en
Open access
Locations
  • BMC Complementary and Alternative Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Bpifrance
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
  • Health Sciences › Nursing › Nutrition and Dietetics › Food composition and properties
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Medicinal Plant Research
Keywords
Cinnamomum zeylanicum, postprandial hyperglycemia, α-amylase inhibition, starch hydrolysis, hydroalcoholic extract, blood glucose, insulin, type 2 diabetes prevention, carbohydrate digestion, healthy volunteers, rats, dose-dependent effects, natural food supplements, oxidative stress, cardiovascular risk, obesity risk, aqueous extract
MeSH terms
Adult, alpha-Amylases, Animals, Blood Glucose, Cinnamomum zeylanicum, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Male, Plant Extracts, Starch, Rats, Wistar, Cross-Over Studies, Postprandial Period, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acute effect of Ceylon cinnamon extract on postprandial glycemia: alpha-amylase inhibition, starch tolerance test in rats, and randomized crossover clinical trial in healthy volunteers. https://app.cochat.ai/papers/10.1186/1472-6882-14-351
The paper
Beejmohun, V., Peytavy-Izard, M., Mignon, C., Muscente-Paque, D., Deplanque, X., Ripoll, C., & Chapal, N. (2014). Acute effect of Ceylon cinnamon extract on postprandial glycemia: alpha-amylase inhibition, starch tolerance test in rats, and randomized crossover clinical trial in healthy volunteers. BMC Complementary and Alternative Medicine. https://doi.org/10.1186/1472-6882-14-351

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.